RxDoctor Payments Data

Thomas Andrew, MD

Family Medicine · Gillette, WYNPI 1821199316

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 30.0% of the total. Reporting peaked in 2021 at $221 and has fallen 80.2% since, to $44 in 2025.

$1,069in general payments, 2019–2025

Across 60 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$321
  • Novo Nordisk$250
  • Lilly USA, LLC$242
  • GSK$52
  • Merck$49
  • Teva Pharmaceuticals USA, Inc.$43
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$1,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 80th percentile of 237 family medicine providers in Wyoming.

See all family medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$49,397
Medicare patients
81
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$18,345
FarxigaDapagliflozin Propanediol20$16,632
OzempicSemaglutide20$16,058
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,552
Buprenorphine Hcl38$2,610
Testosterone11$2,430
Liothyronine Sodium74$2,375
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,703
Oxycodone Hcl90$1,570
Albuterol Sulfate HfaAlbuterol Sulfate30$863
Estradiol (Once Weekly)Estradiol14$816
Potassium Chloride30$801
Pregabalin29$756
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$730
ProgesteroneProgesterone, Micronized15$639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$18,34513 claims
AstraZenecaFarxiga$321$16,63220 claims
Novo NordiskOzempic$250$16,05820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 237 family medicine providers in Wyoming.

Other family medicine in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →